<p>Josh Jennings 给出了买入评级，原因是包括强生在第三季度的财务表现出色。该公司在收入和每股收益方面超出了市场预期，显示出其创新药物和医疗科技部门的强劲增长。这一表现突显了强生有效应对挑战的能力，例如 Stelara 的专利到期，同时在其他制药领域仍实现了显著的销售增长。</p>
<p>此外，强生还提高了其运营销售指引，反映出对未来增长前景的信心。该公司预计运营和报告销售将会增加，这得益于其战略举措和旨在长期增长的投资。计划分拆其骨科部门也被视为进一步扩张的潜在催化剂，这增强了 Jennings 对该股票的积极展望。</p>
<p>根据 TipRanks，Jennings 是一位 3 星分析师，平均回报率为 2.5%，成功率为 47.79%。Jennings 关注医疗保健行业，重点分析 TransMedics Group、波士顿科学和美敦力等股票。</p>
<p>在今天发布的另一份报告中，瑞银也维持了该股票的买入评级，目标价为 214.00 美元。</p>

强生

<p>乔什·詹宁斯对强生公司（Johnson & Johnson）发布了买入评级，指出其第三季度财务表现强劲，超出市场对收入和每股收益的预期。尽管面临如 Stelara 失去独占权等挑战，公司在创新药物和医疗科技领域仍显示出增长。强生已提高其运营销售指引，表明对未来增长的信心，这得益于包括计划分拆其骨科部门在内的战略举措。瑞银（UBS）也维持买入评级，目标价为 214 美元</p>

<p>Josh Jennings has given his Buy rating due to a combination of factors, including Johnson &amp; Johnson’s strong financial performance in the third quarter. The company exceeded market expectations with its revenue and earnings per share, showcasing robust growth in both its Innovative Medicine and MedTech segments. This performance highlights JNJ’s ability to effectively manage challenges, such as the loss of exclusivity for Stelara, while still achieving significant sales growth in other pharmaceutical areas.</p>
<div class="lb-trans"><p>Josh Jennings 给出了买入评级，原因是包括强生在第三季度的财务表现出色。该公司在收入和每股收益方面超出了市场预期，显示出其创新药物和医疗科技部门的强劲增长。这一表现突显了强生有效应对挑战的能力，例如 Stelara 的专利到期，同时在其他制药领域仍实现了显著的销售增长。</p>
</div><p>Additionally, Johnson &amp; Johnson has increased its operational sales guidance, reflecting confidence in its future growth prospects. The company anticipates higher operational and reported sales, supported by its strategic initiatives and investments aimed at long-term growth. The planned separation of its orthopedics division is also seen as a potential catalyst for further expansion, contributing to Jennings’s positive outlook on the stock.</p>
<div class="lb-trans"><p>此外，强生还提高了其运营销售指引，反映出对未来增长前景的信心。该公司预计运营和报告销售将会增加，这得益于其战略举措和旨在长期增长的投资。计划分拆其骨科部门也被视为进一步扩张的潜在催化剂，这增强了 Jennings 对该股票的积极展望。</p>
</div><p>According to TipRanks, Jennings is a 3-star analyst with an average return of 2.5% and a 47.79% success rate. Jennings covers the Healthcare sector, focusing on stocks such as TransMedics Group, Boston Scientific, and Medtronic.</p>
<div class="lb-trans"><p>根据 TipRanks，Jennings 是一位 3 星分析师，平均回报率为 2.5%，成功率为 47.79%。Jennings 关注医疗保健行业，重点分析 TransMedics Group、波士顿科学和美敦力等股票。</p>
</div><p>In another report released today, UBS also maintained a Buy rating on the stock with a $214.00 price target.</p>
<div class="lb-trans"><p>在今天发布的另一份报告中，瑞银也维持了该股票的买入评级，目标价为 214.00 美元。</p>
</div>

强生第三季度的强劲表现和战略举措推动了买入评级